Conceived at the 2024 Biodiversity COP, the Cali Fund was meant to raise billions of dollars for nature protection – but has so far collected only US$7,085 (S$9,060).
asserted
Fund → conceive → 7,085
It is a sluggish start for a fund intended as a showcase for innovative financing that charges companies profiting from the use of genetic data derived from nature.
asserted
that → intend → nature
The trickle of money highlights the difficulties involved in mobilising money for biodiversity.
asserted
trickle → highlight → biodiversity
As a crucial UN biodiversity summit in Armenia running until Oct 30 discusses its future, here is a rundown on how the fund works and reasons for its lacklustre start:
How does the fund work?
Adopted at COP16 in Cali, Colombia, at the end of 2024, the fund began operating in February 2025.
asserted
operating → run → February
It proposes the payment of 1% of the annual profits of pharmaceutical, cosmetics, biotechnology companies or firms specialising in animal and plant breeding, or 0.1% of their turnover.
asserted
It → propose → turnover
In a preparatory document, its designers mentioned the possibility of recovering one billion dollars a year in light of the revenues of the sectors concerned.
asserted
designers → mention → sectors
However, so far only three companies have contributed: The British firms TierraViva AI (US$1,000) and Prozomix (US$5,000), and the Belgian company E-BIOM (US$1,085).
asserted
companies → contribute → firms
Two others have pledged an additional US$3,571.
asserted
others → pledge → 3,571
Digital sequence information (DSI) – data derived from genetic resources such as plants, animals, fungi, viruses and micro-organisms – is freely accessible in digital databases.
asserted
information → derive → databases
Companies draw on this biological heritage to turn it into economic value by developing a medicine, a cream, improving an agricultural plant and so on.
asserted
Companies → draw → plant
The Cali Fund is based on the idea that those who benefit from this information, directly or indirectly, should in return contribute to the protection of biodiversity and to the local communities preserving it.
asserted
who → base → it
The fund is not legally binding but it does invite states to adopt administrative, policy or legislative measures to encourage companies to do so.
asserted
it → invite → companies
The main difficulty is the “mechanism still relies very heavily on incentives and voluntary contributions”, according to Juliette Landry from the sustainable development think tank IDDRI based in Paris.
uncertain
mechanism → rely → Paris
“As long as these incentives are not strong enough and consistent across countries, a company may well ask why it should contribute when its competitors are not doing so.”
uncertain
competitors → ask → countries
Pakhi Das, public policy adviser at the NGO Plant-for-the-Planet, said there were no countries currently with legislation incentivising contributions to the fund, nor are there any where such legislation is under discussion.
asserted
legislation → say → discussion
Beyond the challenge of drawing enough resources into it, another lies in the actual use of the money collected.
asserted
another → draw → money
“The main hurdle that companies seem to be raising is ensuring there are safeguards in place for how their funding will be used,” said Vishaish Uppal, a director at WWF-India.
asserted
Uppal → seem → India
Companies also want to be sure that the Cali Fund’s internationally-accepted certificates – documenting receipt of payment for use of genetic resources – are also accepted nationally, to avoid paying twice.
asserted
certificates → want → resources
What does the pharmaceutical industry say?
asserted
industry → say → What
“The level of participation in the Cali Fund reflects ongoing questions about the design and implementation of the mechanism, rather than a lack of commitment to biodiversity,” said Guilherme Cintra, the director of innovation policy at the International Federation of Pharmaceutical Manufacturers and Associations.
“The current mechanism overlaps with existing law, relies on inaccurate assumptions about how data is used in the discovery of medicines,” he added.
asserted
he → reflect → medicines
Several major cosmetics companies did not respond to AFP’s requests.
asserted
companies → respond → requests
The small amount collected “is not enough (on its own) to determine whether the mechanism is a success or a failure,” said Landry from IDDRI.
asserted
Landry → collect → IDDRI
“In the coming years, the question will be whether governments manage to create the right conditions so that companies marketing products and services based on digital sequence information actually contribute to this mechanism,” she added.
asserted
she → come → mechanism
The Aporia
